OTS - LTS receives $4.3 Million grant for the development of contraceptive Microneedle Array Patches
2023. December 19. 13:00
Andernach, 19 December, 2023 (APA/MTI) - LTS, a leading
pharmaceutical technology company, announced today that it has
received a grant from the Bill & Melinda Gates Foundation. The
purpose of the grant is to support the development of microneedle
array patches (MAP) for self-administration of contraceptives for
women in low- and middle-income countries (LMICs). The grant will
fund $4.3 million over a duration of 25 months.
Poor access to contraceptives presents a significant burden for
women living in LMICs. According to a 2022 study, one in 14 women
worldwide who want to use contraceptives cannot access them*. This
amounts to an unmet need of 162 million women, the majority of whom
live in sub-Saharan Africa and South Asia.
MAPs are an innovative drug delivery technology that offers
advantages in comparison to established drug delivery applications
for contraception such as fewer side effects and potentially
improved bioavailability with therapeutic and cost benefits. The
MAP contraceptive is planned as a long-acting application (6
month). In comparison to other existing long-acting forms it can be
self-administered, is discreet and does not require healthcare
provider visits.
Bas van Buijtenen, CEO of LTS, comments: "At LTS, we care
passionately about bringing patient friendly drug delivery to
people worldwide. We are honoured to receive support from the Gates
Foundation in creating solutions for populations that would
otherwise be at risk of being left behind. With this program, we
aim to deliver improved access to contraception, boosting health
and empowering women."
"The LTS MAP team is excited to have support from the Gates
Foundation for the development of a long-acting contraceptive
Microneedle Array Patch with LTS", said Dr. Frank Theobald, Head of
MAP Program at LTS. "LTS has made great progress recently with
respect to pre-clinical and clinical data, taking major steps
towards the up-scaling and commercialization of the MAP technology.
Based upon those progresses made, we would like to emphasize that
our MAP technology is no longer a vision, but real alternative for
drug delivery of small molecules, vaccines, biologics, and mRNA.
Support from the foundation will help to develop the MAP technology
further and bring it to the next level of maturity and it will
allow women in LIMCs to get access to a reliable and effective way
of contraception and improve their economic situation. That will
support them in establishment of gender equality in their
communities."
LTS has also received funding from the Bill & Melinda Gates
Foundation to support new formulation methods for mRNA, such as
dissolvable microneedle array patches.
About LTS
We CARE. We CREATE. We DELIVER. The driving philosophy behind
LTS. As a trusted technology partner for the pharmaceutical
industry, we develop and manufacture innovative drug delivery
systems such as Transdermal Patches ("TTS") and Oral Thin Films
("OTF") as well as wearable drug delivery devices ("OBDS"). LTS´
commercial offering encompasses more than 20 marketed products and
a diverse pipeline of more than 40 development projects targeting
multiple disease indications. LTS's innovation pipeline contains
both partner-funded as well as proprietary, LTS-funded projects.
LTS maintains its leading position through the continuous
refinement of its core TTS and OTF technologies and by advancing
emerging drug delivery technologies, including Microneedle Array
Patches ("MAP") for the transdermal delivery of small and large
molecules, biological actives and vaccines. With its SorrelTM
wearable drug delivery platform LTS offers patient friendly
solutions for complex drugs delivery at home. Founded in 1984, LTS
operates today from four sites: in Andernach, Germany, West
Caldwell, NJ, USA, St. Paul, MN, USA and Netanya, Israel. LTS has
also a representative office in Shanghai, China.
Picture is available at AP
(https://apmultimedianewsroom.com/multimedia-newsroom/partners/news-aktuell)
*Haakenstad A, Angelino O, Irvine C, Bhutta ZA, Bienhoff K,
Bintz C, Causey K, Dirac MA, Fullman N, Gakidou E, Glucksman T, Hay
SI, Henry NJ, Martopullo I, Mokdad AH, Mumford JE, Lim SS, Murray
CJL, Lozano R. 2022. Measuring contraceptive method mix,
prevalence, and demand satisfied by age and marital status in 204
countries and territories, 1970-2019: a systematic analysis for the
Global Burden of Disease Study 2019. Online: The Lancet. Available
at:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00936-9/fulltext
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók a
forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI által
szó szerint továbbított tartalomért minden esetben a beadó a
felelős.
© Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.